ARTICLE | Company News
FDA to discuss pulmonary compounds
December 1, 2012 2:33 AM UTC
FDA's Pulmonary-Allergy Drugs Advisory Committee will meet on Jan. 29, 2013 to discuss an NDA from Boehringer Ingelheim GmbH (Ingelheim, Germany) for Striverdi Respimat olodaterol to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Boehringer Ingelheim declined to disclose when it submitted the NDA or the PDUFA date for the long-acting beta 2 agonist (LABA). ...